PIAM puts itself forward as a one-stop reference point for specialists, not only offering them an extensive portfolio of pharmaceutical solutions, dietary supplements and medical foods that meets tolerability and efficacy standards, but also developing a strategic relationship with them, making it possible to identify health needs and transform them into research focused on the specialist’s clinical practice and patient wellbeing.
This modus operandi, which underpins PIAM’s Business Model, is reinforced thanks to the company’s “Italianness”, interpreted not only as scientific culture, capacity for innovation and product quality, but above all as the continuity of the relationship with doctors and partners over time.
Scientific excellence and speed of response and supply of targeted therapeutic solutions are key factors for patients. Because of this, PIAM has chosen an Exclusive Business Model that combines internal clinical research with ongoing and continuous global scouting activity, making it possible to identify, study and supply alongside international partners with a high scientific profile the best therapeutic solutions in terms of efficacy and safety during the international study and advanced development phase.
More than twenty years of experience in managing rare diseases, specialisation in medical food and in the treatment of PKU, are translated into an awareness of the complex problems that relatives and caregivers, together with doctors, have to face throughout the patient’s life, in the knowledge that treatment compliance plays a fundamental role in the care process and is key in terms of treatment efficacy.
PIAM puts itself forward as a one-stop reference point for specialists, not only offering them an extensive portfolio of pharmaceutical solutions, dietary supplements and medical foods that meets tolerability and efficacy standards, but also developing a strategic relationship with them, making it possible to identify health needs and transform them into research focused on the specialist’s clinical practice and patient wellbeing.
This modus operandi, which underpins PIAM’s Business Model, is reinforced thanks to the company’s “Italianness”, interpreted not only as scientific culture, capacity for innovation and product quality, but above all as the continuity of the relationship with doctors and partners over time.
Scientific excellence and speed of response and supply of targeted therapeutic solutions are key factors for patients. Because of this, PIAM has chosen an Exclusive Business Model that combines internal clinical research with ongoing and continuous global scouting activity, making it possible to identify, study and supply alongside international partners with a high scientific profile the best therapeutic solutions in terms of efficacy and safety during the international study and advanced development phase.
More than twenty years of experience in managing rare diseases, specialisation in medical food and in the treatment of PKU, are translated into an awareness of the complex problems that relatives and caregivers, together with doctors, have to face throughout the patient’s life, in the knowledge that treatment compliance plays a fundamental role in the care process and is key in terms of treatment efficacy.
Read also
